Biogen Inc. (BIT:1BIIB)

Market Cap	24.99B +24.3%
Revenue (ttm)	8.42B +2.2%
Net Income	1.10B -20.8%
EPS	7.49 -21.4%
Shares Out	n/a
PE Ratio	22.70
Forward PE	13.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112
Average Volume	40
Open	154.35
Previous Close	158.45
Day's Range	154.35 - 163.45
52-Week Range	99.46 - 163.45
Beta	n/a
RSI	68.29
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BIIB

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD